18th Sep 2018 17:48
LONDON (Alliance News) - AstraZeneca PLC on Tuesday said the most recent trial of Fasenra showed that the asthma drug was as effective at reducing adverse events over a two-year period as it was in a single year.
The BORA trial, which followed previous year-long SIROCCO and CALIMA trials, showed Fasenra to have similar levels of safety and tolerability when administered over an additional 52 weeks.
Fasenra treats severe eosinophilic asthma, a type of asthma in which white blood cells called eosinophils cause inflammation of the airways. 74% of the trial's primary efficacy population, patients with a blood eosinophil count of 300 cells per microlitre or higher, were exacerbation-free in their second year of treatment, maintaining both their improved lung function and asthma control.
"The BORA data are important news for patients with severe eosinophilic asthma who need a treatment with sustained efficacy to help control their disease, and with a safety profile that supports long-term use," said Executive Vice President Sean Bohen.
Fasenra is AstraZeneca's first respiratory bioloic and is approved as an add-on treatment for severe eosinophilic asthma in the US, EU and Japan.
Shares in AstraZeneca closed down 0.2% at 5,609.00 pence on Tuesday.
Related Shares:
Astrazeneca